RWA Wealth Partners LLC Takes $3.07 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

RWA Wealth Partners LLC bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, Holdings Channel reports. The institutional investor bought 5,525 shares of the company’s stock, valued at approximately $3,067,000.

Other large investors also recently made changes to their positions in the company. Gotham Asset Management LLC increased its holdings in shares of IDEXX Laboratories by 79.9% in the 3rd quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock valued at $7,620,000 after purchasing an additional 7,741 shares during the period. NewEdge Wealth LLC increased its holdings in IDEXX Laboratories by 30.4% in the third quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock worth $279,000 after buying an additional 149 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in IDEXX Laboratories by 25.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after buying an additional 8,831 shares during the last quarter. Carderock Capital Management Inc. increased its holdings in IDEXX Laboratories by 35.7% in the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock worth $9,112,000 after buying an additional 4,315 shares during the last quarter. Finally, Mitchell Capital Management Co. increased its holdings in IDEXX Laboratories by 1.3% in the third quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock worth $2,786,000 after buying an additional 79 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on IDXX. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Barclays upped their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price for the company. in a research report on Tuesday, January 30th. Finally, The Goldman Sachs Group upped their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $591.50.

Insider Activity at IDEXX Laboratories

In related news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the sale, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock valued at $24,871,960 over the last ninety days. 2.18% of the stock is owned by insiders.

IDEXX Laboratories Stock Up 3.0 %

IDXX opened at $493.80 on Wednesday. The stock has a market capitalization of $41.01 billion, a price-to-earnings ratio of 49.04, a P/E/G ratio of 3.69 and a beta of 1.26. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The business has a 50 day moving average of $535.07 and a 200-day moving average of $510.61. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The company had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. During the same period last year, the business earned $2.05 earnings per share. The business’s revenue was up 8.8% on a year-over-year basis. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.